中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
1期
66-68
,共3页
全身炎症反应综合征%持续高容量血液滤过%血液灌流
全身炎癥反應綜閤徵%持續高容量血液濾過%血液灌流
전신염증반응종합정%지속고용량혈액려과%혈액관류
Systemic inflammatory response syndrome(SIRS)%Continuous high volume hemofiltration(CHVHF)%Hemoperfusion(HP)
目的:观察血液灌流(HP)联合血液滤过(CVVH)在全身炎症反应综合征(SIRS)中的临床应用价值。方法选择50例诊断为SIRS的患者,依照治疗方法将其随机为两组,观察组(n=25)患者采用血液灌流(HP)联合血液滤过(CVVH)治疗,对照组患者单纯采用血液滤过(CVVH)治疗;对比两组患者的临床效果。结果治疗后,两组患者的体温、心率、白细胞计数以及血乳酸、细胞因子等均较治疗前出现显著降低(P<0.05),且观察组患者的各指标下降程度更加明显(P<0.01)。结论在SIRS出现早期联合应用血液灌流及血液滤过能更好地阻断SIRS的发展,降低死亡率,从而获得较好的治疗效果。
目的:觀察血液灌流(HP)聯閤血液濾過(CVVH)在全身炎癥反應綜閤徵(SIRS)中的臨床應用價值。方法選擇50例診斷為SIRS的患者,依照治療方法將其隨機為兩組,觀察組(n=25)患者採用血液灌流(HP)聯閤血液濾過(CVVH)治療,對照組患者單純採用血液濾過(CVVH)治療;對比兩組患者的臨床效果。結果治療後,兩組患者的體溫、心率、白細胞計數以及血乳痠、細胞因子等均較治療前齣現顯著降低(P<0.05),且觀察組患者的各指標下降程度更加明顯(P<0.01)。結論在SIRS齣現早期聯閤應用血液灌流及血液濾過能更好地阻斷SIRS的髮展,降低死亡率,從而穫得較好的治療效果。
목적:관찰혈액관류(HP)연합혈액려과(CVVH)재전신염증반응종합정(SIRS)중적림상응용개치。방법선택50례진단위SIRS적환자,의조치료방법장기수궤위량조,관찰조(n=25)환자채용혈액관류(HP)연합혈액려과(CVVH)치료,대조조환자단순채용혈액려과(CVVH)치료;대비량조환자적림상효과。결과치료후,량조환자적체온、심솔、백세포계수이급혈유산、세포인자등균교치료전출현현저강저(P<0.05),차관찰조환자적각지표하강정도경가명현(P<0.01)。결론재SIRS출현조기연합응용혈액관류급혈액려과능경호지조단SIRS적발전,강저사망솔,종이획득교호적치료효과。
Objective To observe the clinical application value of hemoperfusion(HP) combined with continuous veno venous hemofiltration(CVVH) in systemic inflammatory response syndrome(SIRS). Methods Fifty patients diagnosed SIRS were randomly divided into the two groups according to the treatment methods,the patients in the observation group(n=25) were treated with the HP combined with CVVH therapy,while the patients in the control group were only treated with the CVVH therapy.The clinical effect of patients in the two groups were compared. Results Compared with before the treatment,the body temperature,heart rate,white blood cell count and blood lactic acid, cytokines of patients in the two groups after the treatment decreased significantly(P<0.05),and the indexes of patients in the observation group declined more obviously(P<0.01). Conclusion HP combined with CVVH therapy in the early SIRS can effectively block the development of SIRS,reduce the mortality rate,so as to gain a better therapeutic effect.